Pricing Component Data - Rule Chapter 570

This data is covered under Rule Chapter 570, which was adopted and is effective as of December 10, 2021

12/14/21 - Upcoming Pharma Data Webinar - Chapter 570 Prescription Drug Price Data

In January 2022, the MHDO will release an update to the MHDO Prescription Drug Price Data Portal that will include the latest revisions to 90-590 Chapter 570: Uniform Reporting System for Prescription Drug Price Data Sets. Please see the summary of changes in the Basis Statement.

The MHDO will host a webinar on Tuesday, January 11, from 1-2 PM ET to discuss and respond to questions regarding Chapter 570 file format changes and other changes that were required to reconcile the rule with recent changes in Maine law. The MHDO will also review the requirements and timeline for Chapter 570 Uniform Reporting System for Prescription Drug Price Data Sets. A recording of the webinar will be available for those who are unable to attend the session.

Join the Webinar via Zoom Meeting:

  • URL: Click this link or copy and paste URL (https://zoom.us/j/93268543865) into browser
  • Meeting ID: 932 6854 3865
  • One tap mobile +13126266799, ,93268543865# US (Chicago)
    +16465588656, ,93268543865# US (New York)

Please note these important tasks and dates for the submission of Chapter 570 Prescription Drug Price Data.

Task Start Date End Date
Webinar to review Chapter 570 2022 registration and reporting requirements Tue 1/11/22 Tue 1/11/22
MHDO Prescription Drug Price Data Portal 2022 registration must be completed Sat 1/1/22 Sun 1/30/22
The MHDO produces and posts on its publicly available website a list of drug product families for which it intends to request pricing component data from manufacturers, wholesale drug distributors and pharmacy benefits managers Tue 2/1/22 Tue 2/15/22
HSRI, MHDO's data vendor, notifies manufacturers, wholesale distributers and PBMs via email that prepopulated Pricing Component Data templates, including specific NDCs for which reporting is required, are available for download from the MHDO Prescription Drug Price Data Portal Thu 3/17/22 Thu 3/17/22
Completed Pricing Component Data templates are due Mon 5/16/22 Mon 5/16/22

Important Notes

  1. LD 686, An Act to Increase Prescription Drug Price Transparency passed in the last session as Public Law 2021, Chapter 305, and became effective October 18, 2021. Several provisions in Rule Chapter 570 were inconsistent with the new law. When this occurs, the statute overrides inconsistencies in the rule. The rule now includes three notes that address the inconsistencies in the new law and the earlier version of the proposed rule.
    1. As of reporting year 2022, the MHDO will be posting a list of these NDCs and the manufacturers will no longer have to make such notifications to the MHDO. PL 2021, c. 305, Sections 4 & 5 [Chapter 570 Section 2(B)(3), page 4]
    2. As of reporting year 2022, the MHDO will be posting a list of these NDCs and the manufacturers will no longer have to make such notifications to the MHDO. PL 2021, c. 305, Sections 4 & 5 [Chapter 570 Section 2(C)(1)(a), page 4]
    3. As of October 18, 2021, The MHDO may share information in the aggregate, even if it allows the identification of an individual drug, as long as it is not released in a manner that allows the determination of individual prescription drug pricing contract terms covering a manufacturer, wholesale drug distributor or pharmacy benefits manager. PL 2021, c. 305, Sections 7 & 9. (Chapter 570 Section (6)(B), page 11]
  2. Enforcement issue: The level of reporting for the Pharmacy Benefit Managers in Chapter 570 was agreed to in the HCIFS committee work session, but was inadvertently not included in the final version of the rule.
    Resolution: The Board of Directors of the MHDO hereby partially suspends enforcement of 90-590 CMR Chapter 570, Section 2(J)(3) so that the MHDO shall enforce collection of the pricing component data from Pharmacy Benefits Mangers only for the data relevant to Maine, rather than the United States, including for each NDC the Pricing Units Administered, the Total Pharmacy Reimbursement, the Total Payment Received, the Total Rebate Receivable, the Total Rebate Payable Amount and any additional information, if applicable.